AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02675842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smoked Cannabis High CBD/low THC
Description: Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
Study NCT02675842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Smoked Placebo Cannabis Low CBD/low THC
Description: Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
Study NCT05038462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin and DHA
Description: The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily
Study NCT05038462 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product with the same physical appearance and taste as the main intervention but without therapeutic effect
Study NCT05424172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage-I, Group 1: Self monitoring using Non-interactive App
Description: Participants in Group 1 will have minimal features that affect compliance (notifications, rewards, EMA, etc.) and no modifications to their exercise program after initial prescription.
Study NCT05424172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage-I, Group 2: Self monitoring using Interactive App
Description: Participants in Group 2 will use the version of the exercise app that has been modified based on the findings from Phases 1 and 2 of this study. Group 2 will be able to use the full features of the interactive app including notifications, ability to submit videos, and non-synchronous messaging/communicating with the researcher. Additionally, participants in Group 2 will be asked to complete 2-5 EMA-based surveys daily to gain information about the participant's barriers and facilitators to exercise. The information from the EMA questionnaires will be used to progress and modify the exercise program at regular intervals for each participant in Group 2.
Study NCT05424172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage-II, Groups 1a/2a: E-Coaching 2x per month
Description: In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions two times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
Study NCT05424172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage-II, Groups 1b/2b: E-Coaching 4x per month
Description: In addition to the Stage-I assigned app, participants will be asked to complete at least daily EMA questionnaires and e-coaching sessions four times a month throughout Stage-II (weeks 13-24). Participants will only receive the augmented e-coaching intervention if they were not adherent to the exercise guidelines for at least 50% of the weeks during Stage-I (weeks 1-12).
Study NCT05542550 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice Rest
Description: Voice rest restricting patient phonation
Study NCT05542550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Voice Rest
Description: No Voice rest
Study NCT03553914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLM60
Description: PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.
Study NCT05291442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To integrate Family System Care and Theme Care Action Module
Description: First, understand the care needs of patients and caregivers, and apply The Specific Thematic Nursing Care Action Modules (STNC-AM) platform for education and training.~The Specific Thematic Nursing Care Action Modules (STNC-AM) platform that we present here is an educational program that integrates education and coaching. STNC-AM has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. Each scope contains detailed care guidance.
Study NCT06466785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efepoetin Alfa
Description: Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine, intended for treatment and maintenance of anemia due to CKD with or without dialysis. Its drug substance is a recombinant form of human EPO and hybrid Fc (hyFc®) fragment consisting of 2 subunits with a total of 411 amino acid residues. Each subunit contains an EPO molecule linked to a hybrid Fc fragment of c terminal of CH2 and CH3 regions from IgG4 and to N-terminal of CH2 region and the hinge sequence from IgD. These 2 subunits are joined by a single disulfide bond at the hinge region of each subunit. Half-life is 138.5-157.9 hours. It is an acidic glycoprotein of about 30 kDa and comprises 165 amino acids and 4 glycans. Circulating EPO exhibits several glycosylation isoforms that differ in electrical charge and biological activity
Study NCT06466785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin Alfa
Description: Darbepoetin alfa is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy
Study NCT05962047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Games of WonderTree Augmented Reality
Description: Participants of group 1 (experimental group) will augmented reality based interventions comprising of games of Wonder Tree
Study NCT05962047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional therapy
Description: Traditional therapy based on play activities utilizing blocks, colors, Velcro-based toys.
Study NCT06396585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 ,Q3W
Study NCT06396585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Participants will receive anlotinib,12mg, qd，d1-d14，Q3W
Study NCT06396585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive Oxaliplatin, 130mg/m2, iv, day 1 ,Q3W
Study NCT06396585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Participants will receive S-1 40-60mg/m2/c次，bid ，d1-d14，Q3W
Study NCT04434599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopically guided ablation
Description: Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by fluoroscopy
Study NCT04434599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact force guided ablation
Description: Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by contact force measurement and 3D electroanatomic mapping
Study NCT04434599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local impedance guide ablation
Description: Catheter ablation of the cavotricuspid isthmus using ablation catheters guided by local impedance measurement and ultra-high density 3D electroanatomic mapping
Study NCT05476042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prescription of placebo
Description: Normal saline
Study NCT05476042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin prescription
Description: Erythropoietin 3000 units in normal saline
Study NCT05476042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin prescription
Description: Erythropoietin 6000 units in normal saline
Study NCT06010498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eye mask
Description: * First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given + eye patch will be applied (22:00-06:00)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled
Study NCT06010498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standart care
Description: Control group (n)~* First day morning The Introductory Characteristics Form will be filled.~* First day night Standard care will be given~* Second day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Second day night Standard care will be given~* Third day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled~* Third day night Standard care will be given)~* Fourth day morning Richards-Campbell Sleep Questionnaire and Numerical Pain Scale to be filled
Study NCT05328726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR-18
Description: As previously described in Arms
Study NCT05328726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be dosed in an identical manner to active study drug.
Study NCT05435170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linerixibat
Description: linerixibat will be administered per the treatment sequence
Study NCT04982263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood coagulation profile
Description: Venous blood sample for measurement of blood coagulation profile
Study NCT06323603 — intervention group
Intervention type: OTHER
Intervention: Micro and nanoplastic
Description: Biological samples will be obtained to evaluate the different biomarkers selected
Study NCT05449197 — intervention group
Intervention type: OTHER
Intervention: HEMOPHAR e-learning program
Description: training on professional practice by following HEMOPHAR e-learning program
Study NCT06043115 — intervention group
Intervention type: OTHER
Intervention: covid-19 survival cohort
Description: consists of surviving patients
Study NCT06043115 — intervention group
Intervention type: OTHER
Intervention: covid-19 mortality cohort
Description: consists of deceased patients
Study NCT05492734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDG-5506
Description: single oral dose
Study NCT05577286 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: regular care
Description: the regular medical treatment without change of their daily activity routine
Study NCT05577286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular care
Description: the regular medical treatment without change of their daily activity routine
Study NCT05577286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric training
Description: designed plyometric training program for 30 minutes, three times a week for two successive months
Study NCT05444842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: insulin iontophoresis
Description: All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent). after cleaning the wound the insulin ions and oleic acid will be injected into the electrode of iontophoresis device (Phoresor_ IIAuto, ModelPM850, IOMED) then The device was set to the required dose of 40 mA-min, and the current intensity was gradually increased based on the subject's tolerance (ranging from 1 to 4 mA). The device computed the required time for the selected dose automatically.
Study NCT05444842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical insulin
Description: All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of the wound, patients will get ten units (0.1 mL) of insulin crystal in solution with 1mL saline (0.9 percent). An insulin syringe needle was used to spray the solution twice daily on the wound area.
Study NCT05444842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: All wounds will be thoroughly cleansed with physiologic serum before the therapeutic treatment began (i.e., saline 0.9 percent) after cleaning the wound For each 10cm2 of wound 1mL 0.9 percent saline was given.
Study NCT04925167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Argatroban continuous intravenous injection maintained APTT at 1.5 times of baseline.
Study NCT04925167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Description: unfractionated heparin continuous intravenous injection maintained APTT at 1.5 times of baseline.
Study NCT05075837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virus -specific T cells
Description: The product is obtained by leukapheresis of a family donor responsive to the virus: consists of virus- specific T lymphocytes (both CD4+ and CD8+) resuspended in PBS / EDTA buffer plus 0.5% Albumin Human. The productive process lasts two consecutive days and includes two phases: a brief activation with specific viral peptide followed by immunomagnetic separation using the CliniMACS® CCS (IFNγ) capture system which allows a fast and automated separation of IFNγ secreting lymphocytes
Study NCT04942652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Description: Itraconazole 100 mg capsule x 2
Study NCT04942652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Description: Esomeprazole 40 mg tablet x 1
Study NCT05336916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy
Description: Mindfulness-based Cognitive Behavioural Therapy
Study NCT06037902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: patients undergo simulation twice, with and without CPAP
Study NCT04745013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIORITY
Description: PeRsonalIzed remOtely guided preventive exeRcIse therapy for a healThY heart
Study NCT04745013 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Only a written personalized exercise prescription will be provided.
Study NCT06033885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PONDUS®
Description: PONDUS® is a CE-marked medical device to support the positioning of the user in a R82 standing frame.~PONDUS® is designed as a pair of instrumented foot plates and an app as an external display.~PONDUS® gives individual readings from the right and the left plate telling how much force is applied to each plate by combining high frequency data from three pressure sensors in each plate. The data is displayed in the app as a time series graph and can also be exported.
Study NCT04924712 — intervention group
Intervention type: OTHER
Intervention: Measurement of blood immune populations and microbiota distribution.
Description: Measurement of peripheral cell populations by spectral cytometry and in parallel, sequencing of intestinal and urinary bacterial 16S RNA of each patient.
Study NCT04841824 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Observational study. Groups are defined based on baseline patients' characteristics : presence or absence of sepsis.
Study NCT05080699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peptamen Intense VHP, Nestlé Health Science, Switzerland
Description: An enteral formula containing hydrolyzed whey protein, maltodextrin, long-chain triglycerides, medium chain triglycerides (MCT), vitamins and minerals. Compared to standard enteral formula, Peptamen Intense is higher in protein (37 kcal%) and lower in carbohydrates (29 kcal%). The energy content is 1.0 kcal/mL.
Study NCT05781230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Exercises Program
Description: HIE program consisted of ankle pump exercise, Quadriceps isometric exercise, Terminal extension exercise, Passive-active assistive-active range of motion exercise, Heel sliding exercise, Straight leg raise exercise. All exercises were performed for 3 sets of 15 repetitions.
Study NCT05781230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercises Program
Description: LIE program: LIE program was similar to the HIE program. Main differences from the HIE program was repetitions of exercises. All exercises were performed by the patients for 2 sets of 8 repetitions and CPM sessions lasted each exercises session. LIE program took thirty minutes while HIE program lasted sixty minutes. Exercise intensity was monitored using the rating of perceived exertion (RPE) scale, maintaining a range between 6 and 20 RPE (16). PRE\< 8 indicates low intensity, PRE>14 indicates high intensity
Study NCT05242042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT001
Description: JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
Study NCT05242042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
Study NCT04983173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian Stimulation with CC+rFSH
Description: : CC 50 mg/day (Omifin®) + rFSH 150 IU (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
Study NCT04983173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian Stimulation with rFSH
Description: rFSH 300 IU rFSH (Ovaleap®) GnRH antagonist: ganirelix 0.25 mg (Orgalutran®) Recombinant human chorionic gonadotropin (rhCG) 250 μg (Ovitrelle®) micronized progesterone 200 mg 3id (Utrogestan®)
Study NCT05322928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement in daily occupations
Description: The 12-week occupational therapy individual person-centered intervention will be delivered by an occupational therapist according to the individual intervention plan, with a 1-hour video appointment (Region Zealand VDX-connection) a week in four weeks and a maintenance phase of similar session format every second week in two months.~The intervention will include identification of occupational problems that limit compliance with the PA recommendations, setting tailored occupational goals to enhance physically active lifestyle, supervised goal work and goal evaluation. Through active involvement in value-based prioritizing, planning and performance of meaningful everyday activities, the participants will reduce their sedentary time. Changing health behaviour in a stepwise manner, the participants will become prepared for continuous lifestyle goal work as self-management which will allow for sustainable lifestyle changes, and thus, improved long-term health and quality of life.
Study NCT04973982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Envarsus
Description: 3 month treatment, given once daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
Study NCT04973982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adoport
Description: 3 month treatment, given twice daily, oral tablet. Dose titrated according to levels target 6-10ng/ml
Study NCT05125068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1501
Description: AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
Study NCT06209008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravesical injection of Platlet Rich Plasma (PRP)
Description: Patients will receive 20 submucosal injections of PRP solution, each injection site receives 0.5 mL PRP. The injection needle will be inserted about 1 mm into the at the posterior and lateral walls of the bladder, using a 23 gauge needle and 22 F rigid cystoscope.
Study NCT05361109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: The investigational medicinal product (IP) for this study is baricitinib 2mg. The dose will be administered as one 2mg tablet by mouth once daily for the first 8 weeks of study. If no unexpected serious adverse events related to baricitinib in the opinion of the investigator occur during the first 8 weeks of treatment, the dose will be increased to two 2mg tablets (4mg daily) for the remaining 16 weeks of study. All study participants will take baricitinib in combination with standard of care background therapy.
Study NCT06313450 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: de-escalated radiotherapy
Description: Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with a tumor volume regression of 75% or more and no detectable EBV DNA will receive de-escalated radiotherapy for the primary tumor with 60 Gy. During radiotherapy, patients will receive Cisplatin 100 mg/m2 every three weeks for two courses and Toripalimab 240 mg every three weeks for three courses. If patients do not achieve complete remission at the end of radiotherapy, 6 Gy will be added to the residual lesions.
Study NCT06313450 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: conventional radiotherapy
Description: Enrolled patients receive three courses of induction therapy with gemcitabine and cisplatin, along with Toripalimab. After induction therapy, patients with tumor volume regression less than 75% or EBV DNA copy number higher than 0 receive conventional radiotherapy for the primary tumor with 70 Gy. Patients will receive Cisplatin 100 mg/m2, every three weeks for two courses during radiotherapy.